Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension (2023)
- Authors:
- Autor USP: SOUZA, ROGÉRIO DE - FM
- Unidade: FM
- DOI: 10.1183/13993003.01347-2022
- Subjects: SOBREVIDA; HIPERTENSÃO PULMONAR
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: European respiratory journal
- ISSN: 0903-1936
- Volume/Número/Paginação/Ano: v. 61, n. 1, article ID 2201347, 12p, 2023
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
HUMBERT, Marc et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. European respiratory journal, v. 61, n. 1, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/52885. Acesso em: 10 fev. 2026. -
APA
Humbert, M., Mclaughlin, V., Gibbs, J. S. R., Gomberg-Maitland, M., Hoeper, M. M., Preston, I. R., et al. (2023). Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. European respiratory journal, 61( 1). doi:10.1183/13993003.01347-2022 -
NLM
Humbert M, Mclaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R de, Waxman AB, Ghofrani H-A, Subias PE. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension [Internet]. European respiratory journal. 2023 ; 61( 1):[citado 2026 fev. 10 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52885 -
Vancouver
Humbert M, Mclaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R de, Waxman AB, Ghofrani H-A, Subias PE. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension [Internet]. European respiratory journal. 2023 ; 61( 1):[citado 2026 fev. 10 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52885 - Incidência de hematomas subdurais espontâneos em casos de pacientes com hipertensão arterial pulmonar: Análise de um registro de cinco anos
- Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. [Carta]
- Pulmonary hypertension in sickle cell disease
- Challenging the concept of adding more drugs in pulmonary arterial hypertension [Editorial]
- Pulmonary arterialhHypertension-related morbidity is prognostic for mortality
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
- RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study
- 2016 – Um segundo passo [Editorial]
- Building the Future of Trial Design in PAH on Solid Ground
- Goal-oriented treatment of pulmonary arterial hypertension
Informações sobre o DOI: 10.1183/13993003.01347-2022 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
